Micronized palmitoylethanolamide/trans-polydatin treatment of endometriosis-related pain: a meta-analysis
Meta-analysisHumansWith transpolydatin
This study tested palmitoylethanolamide together with transpolydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Meta-analysis
- Subjects
- 4 studies, which the authors rate as poor quality
- Dose used in the study
- Micronised palmitoylethanolamide 400 mg with transpolydatin 40 mg twice a day
- Duration
- 3 months
- What was measured
- Change in pain scores for chronic pelvic pain, dysmenorrhoea, dyspareunia and dyschezia from baseline to 3 months.
What the authors reported
Across a mixed sample, the combination gave a clinically relevant improvement in pelvic pain and dysmenorrhoea, a limited improvement in deep dyspareunia and none in dyschezia.
Limits of this study
Four poor-quality studies, the authors' own description, most without a control group, so the pooled change is before-and-after, not against placebo. The authors call for more studies. Published by the Italian national health institute.
Source
PubMed 28617258 · doi:10.4415/ANN_17_02_08
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.